[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IN2014DN06220A - - Google Patents

Download PDF

Info

Publication number
IN2014DN06220A
IN2014DN06220A IN6220DEN2014A IN2014DN06220A IN 2014DN06220 A IN2014DN06220 A IN 2014DN06220A IN 6220DEN2014 A IN6220DEN2014 A IN 6220DEN2014A IN 2014DN06220 A IN2014DN06220 A IN 2014DN06220A
Authority
IN
India
Prior art keywords
exons
dystrophin gene
human dystrophin
oligomer
drug
Prior art date
Application number
Other languages
English (en)
Inventor
Naoki Watanabe
Haruna Seo
Shinichi Takeda
Tetsuya Nagata
Original Assignee
Nippon Shinyaku Co Ltd
Nat Ct Neurology & Psychiatry
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd, Nat Ct Neurology & Psychiatry filed Critical Nippon Shinyaku Co Ltd
Publication of IN2014DN06220A publication Critical patent/IN2014DN06220A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111General methods applicable to biologically active non-coding nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/314Phosphoramidates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3212'-O-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3222'-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/323Chemical structure of the sugar modified ring structure
    • C12N2310/3233Morpholino-type ring
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/33Alteration of splicing

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
IN6220DEN2014 2011-12-28 2012-12-27 IN2014DN06220A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011288040 2011-12-28
JP2012043092 2012-02-29
PCT/JP2012/084295 WO2013100190A1 (ja) 2011-12-28 2012-12-27 アンチセンス核酸

Publications (1)

Publication Number Publication Date
IN2014DN06220A true IN2014DN06220A (ja) 2015-10-23

Family

ID=48697653

Family Applications (1)

Application Number Title Priority Date Filing Date
IN6220DEN2014 IN2014DN06220A (ja) 2011-12-28 2012-12-27

Country Status (12)

Country Link
US (4) US9512424B2 (ja)
EP (2) EP2799548B1 (ja)
JP (5) JP6141770B2 (ja)
KR (2) KR102071729B1 (ja)
CN (10) CN107881175B (ja)
AU (2) AU2012360702C1 (ja)
CA (2) CA3132111A1 (ja)
ES (1) ES2748868T3 (ja)
IN (1) IN2014DN06220A (ja)
RU (3) RU2619184C2 (ja)
TW (1) TWI606059B (ja)
WO (1) WO2013100190A1 (ja)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1766010T3 (pl) 2004-06-28 2011-07-29 Univ Western Australia Antysensowne oligonukleotydy do indukcji pominięcia egzonu i sposoby ich zastosowania
AU2006213686A1 (en) 2005-02-09 2006-08-17 Avi Bio Pharma, Inc. Antisense composition and method for treating muscle atrophy
EP3238737B1 (en) 2007-10-26 2022-04-06 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
EP3428278A1 (en) 2008-10-24 2019-01-16 Sarepta Therapeutics, Inc. Multiple exon skipping compositions for dmd
PT2499249T (pt) 2009-11-12 2018-11-21 Univ Western Australia Moléculas antisentido e métodos para tratar patologias
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
AU2012360702C1 (en) * 2011-12-28 2018-09-20 National Center Of Neurology And Psychiatry Antisense nucleic acid
CN112251436A (zh) 2012-01-27 2021-01-22 比奥马林技术公司 治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸
CN105378081B (zh) 2013-03-14 2019-06-14 萨勒普塔医疗公司 用于治疗肌营养不良的外显子跳跃组合物
BR112015022998A2 (pt) 2013-03-15 2017-11-14 Sarepta Therapeutics Inc composições melhoradas para o tratamento de distrofia muscular
UA120849C2 (uk) * 2014-03-12 2020-02-25 Ніппон Шин'Яку Ко., Лтд. Антисенсовий олігомер
US10174319B2 (en) 2014-05-19 2019-01-08 Knc Laboratories Co., Ltd. Nucleic acid drug for inducing skipping of variant exon of CD44 gene and increasing expression of normal type CD44 mRNA
CA2951221A1 (en) 2014-06-17 2015-12-23 Nippon Shinyaku Co., Ltd. Antisense nucleic acids
CN106795186B (zh) * 2014-10-14 2021-03-02 味之素株式会社 吗啉代寡核苷酸的制备方法
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
PL3351633T3 (pl) * 2015-09-15 2020-11-02 Nippon Shinyaku Co., Ltd. Antysensowny kwas nukleinowy
BR112018007066A2 (pt) 2015-10-09 2018-10-23 Sarepta Therapeutics Inc composições e métodos para tratamento da distrofia muscular de duchene e distúrbios relacionados
US20190127733A1 (en) 2015-10-09 2019-05-02 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
EP3464305B1 (en) * 2016-05-24 2024-08-21 Sarepta Therapeutics, Inc. Processes for preparing oligomers
EP3464306B1 (en) * 2016-05-24 2024-03-27 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
MX2018016052A (es) * 2016-06-30 2019-05-02 Sarepta Therapeutics Inc Oligomeros de omision de exon para distrofia muscular.
JP2020500541A (ja) * 2016-12-08 2020-01-16 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム ヒト化デュシェンヌ型筋ジストロフィー変異を有するdmdレポーターモデル
MX2019006882A (es) 2016-12-19 2019-08-16 Sarepta Therapeutics Inc Conjugados de oligomeros de omision de exon para distrofia muscular.
MX2019006989A (es) 2016-12-19 2019-08-16 Sarepta Therapeutics Inc Conjugados de oligomeros de omision de exon para distrofia muscular.
EP4115908A1 (en) 2016-12-19 2023-01-11 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
EA201991450A1 (ru) 2017-09-22 2019-12-30 Сарепта Терапьютикс, Инк. Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
US20210145852A1 (en) 2017-09-28 2021-05-20 Sarepta Therapeutics, Inc. Combination Therapies for Treating Muscular Dystrophy
US10765760B2 (en) 2018-05-29 2020-09-08 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
KR20210081322A (ko) 2018-08-02 2021-07-01 다인 세라퓨틱스, 인크. 근육 표적화 복합체 및 디스트로핀병증을 치료하기 위한 그의 용도
AU2019316103A1 (en) 2018-08-02 2021-03-11 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
KR20210104759A (ko) * 2018-12-13 2021-08-25 사렙타 쎄러퓨틱스 인코퍼레이티드 근 이영양증을 위한 엑손 스키핑 올리고머 접합체
WO2020136696A1 (ja) * 2018-12-25 2020-07-02 国立研究開発法人国立精神・神経医療研究センター 随時尿中細胞を用いた筋系細胞の誘導方法
US20230045557A1 (en) 2019-12-19 2023-02-09 Nippon Shinyaku Co., Ltd. Antisense nucleic acid enabling exon skipping
CN118109468A (zh) 2019-12-26 2024-05-31 日本新药株式会社 诱导外显子50的跳读的反义核酸
BR112023021849A2 (pt) 2021-04-30 2023-12-19 Sarepta Therapeutics Inc Métodos de tratamento para distrofia muscular
EP4342498A1 (en) 2021-05-13 2024-03-27 National University Corporation Chiba University Antisense oligomer
EP4361269A1 (en) 2021-06-23 2024-05-01 Nippon Shinyaku Co., Ltd. Combination of antisense oligomers
AU2022306820A1 (en) 2021-07-08 2024-01-04 Nippon Shinyaku Co., Ltd. Nephrotoxicity reducing agent
CA3225573A1 (en) 2021-07-08 2023-01-12 Nippon Shinyaku Co., Ltd. Precipitation suppressing agent
TW202308664A (zh) 2021-07-08 2023-03-01 日商日本新藥股份有限公司 腎毒性減輕劑
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
CA3226365A1 (en) * 2021-07-09 2023-01-12 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
AU2022309028A1 (en) 2021-07-09 2024-01-25 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating dystrophinopathies
JPWO2023026994A1 (ja) 2021-08-21 2023-03-02
AU2022424485A1 (en) 2021-12-27 2024-07-11 Nippon Shinyaku Co., Ltd. Method for producing oligonucleic acid compound
WO2023168427A1 (en) 2022-03-03 2023-09-07 Yale University Compositions and methods for delivering therapeutic polynucleotides for exon skipping
WO2023171820A1 (ja) * 2022-03-11 2023-09-14 日本新薬株式会社 キャリアペプチドが連結された核酸
KR20240155352A (ko) 2022-03-17 2024-10-28 사렙타 쎄러퓨틱스 인코퍼레이티드 포스포로디아미데이트 모르폴리노 올리고머 접합체

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0962463B1 (en) 1989-12-20 2002-07-10 Antivirals Inc. Uncharged morpholino-based polymers having phosphorus-containing chiral intersubunit linkages
JP2924179B2 (ja) 1993-02-19 1999-07-26 日本新薬株式会社 グリセロール誘導体,デバイス及び医薬組成物
ES2310924T3 (es) * 1993-07-13 2009-01-16 Centelion Vectores adenovirales defectivos y utilizacion en terapia genica.
US6727355B2 (en) * 2000-08-25 2004-04-27 Jcr Pharmaceuticals Co., Ltd. Pharmaceutical composition for treatment of Duchenne muscular dystrophy
EP1191097A1 (en) * 2000-09-21 2002-03-27 Leids Universitair Medisch Centrum Induction of exon skipping in eukaryotic cells
EP2374885A3 (en) * 2002-11-25 2012-02-15 Masafumi Matsuo ENA nucleic acid drugs modifying splicing in mRNA precursor
WO2004083432A1 (en) 2003-03-21 2004-09-30 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
PL1766010T3 (pl) 2004-06-28 2011-07-29 Univ Western Australia Antysensowne oligonukleotydy do indukcji pominięcia egzonu i sposoby ich zastosowania
JPWO2006038608A1 (ja) 2004-10-05 2008-05-15 日本新薬株式会社 オリゴ二本鎖rna及び医薬組成物
AU2006237727B2 (en) * 2005-04-22 2012-06-28 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mRNA by interfering with the binding of SR proteins and by interfering with secondary RNA structure.
WO2006129594A1 (ja) 2005-05-30 2006-12-07 Nippon Shinyaku Co., Ltd. 核酸含有複合体製剤の製造方法
US8067571B2 (en) * 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
EP1857548A1 (en) * 2006-05-19 2007-11-21 Academisch Ziekenhuis Leiden Means and method for inducing exon-skipping
WO2008096690A1 (ja) 2007-02-05 2008-08-14 Nippon Shinyaku Co., Ltd. ポリエチレングリコール誘導体
EP3238737B1 (en) * 2007-10-26 2022-04-06 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
DK2207779T3 (da) 2007-11-15 2014-07-14 Sarepta Therapeutics Inc Fremgangsmåde til syntese af morpholinooligomerer
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
US8084601B2 (en) 2008-09-11 2011-12-27 Royal Holloway And Bedford New College Royal Holloway, University Of London Oligomers
EP3428278A1 (en) * 2008-10-24 2019-01-16 Sarepta Therapeutics, Inc. Multiple exon skipping compositions for dmd
CA2741629C (en) 2008-10-27 2022-07-05 Academisch Ziekenhuis Leiden Methods and means for efficient skipping of exon 45 in duchenne muscular dystrophy pre-mrna
US20120046342A1 (en) * 2009-04-24 2012-02-23 Prosensa Technologies B.V. Oligonucleotide comprising an inosine for treating dmd
US20120270930A1 (en) * 2009-10-29 2012-10-25 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Methods and compositions for dysferlin exon-skipping
PT2499249T (pt) * 2009-11-12 2018-11-21 Univ Western Australia Moléculas antisentido e métodos para tratar patologias
CN107353317A (zh) 2010-05-28 2017-11-17 萨勒普塔医疗公司 具有修饰的亚基间键和/或端基的寡核苷酸类似物
JP5593949B2 (ja) 2010-08-17 2014-09-24 横河電機株式会社 プログラマブルロジックコントローラ
AU2012360702C1 (en) * 2011-12-28 2018-09-20 National Center Of Neurology And Psychiatry Antisense nucleic acid

Also Published As

Publication number Publication date
CN110079525A (zh) 2019-08-02
EP2799548A1 (en) 2014-11-05
EP2799548B1 (en) 2019-08-21
ES2748868T3 (es) 2020-03-18
US10781448B2 (en) 2020-09-22
AU2018229530B2 (en) 2021-05-13
JPWO2013100190A1 (ja) 2015-05-11
CA2861247C (en) 2021-11-16
JP2020114215A (ja) 2020-07-30
CN108588073A (zh) 2018-09-28
AU2012360702A1 (en) 2014-07-24
RU2681470C1 (ru) 2019-03-06
CN110055243A (zh) 2019-07-26
US9512424B2 (en) 2016-12-06
US20170067052A1 (en) 2017-03-09
JP7038365B2 (ja) 2022-03-18
US9890381B2 (en) 2018-02-13
CN108486116A (zh) 2018-09-04
RU2651468C1 (ru) 2018-04-19
CN117721110A (zh) 2024-03-19
TW201336859A (zh) 2013-09-16
AU2012360702C1 (en) 2018-09-20
US20210222169A1 (en) 2021-07-22
CN110055244A (zh) 2019-07-26
CN108611349A (zh) 2018-10-02
RU2619184C2 (ru) 2017-05-12
KR102071729B1 (ko) 2020-01-31
EP2799548A4 (en) 2015-11-18
CA2861247A1 (en) 2013-07-04
KR20140108676A (ko) 2014-09-12
CN107881175A (zh) 2018-04-06
EP3594347A1 (en) 2020-01-15
US20180142245A1 (en) 2018-05-24
JP2024038103A (ja) 2024-03-19
AU2012360702B2 (en) 2018-06-28
CA3132111A1 (en) 2013-07-04
KR102240139B1 (ko) 2021-04-13
JP2017163994A (ja) 2017-09-21
JP6734222B2 (ja) 2020-08-05
CN110055243B (zh) 2024-03-26
CN104024414A (zh) 2014-09-03
KR20200008663A (ko) 2020-01-28
TWI606059B (zh) 2017-11-21
JP6141770B2 (ja) 2017-06-07
JP2022058379A (ja) 2022-04-12
CN107881175B (zh) 2022-05-13
RU2014130600A (ru) 2016-02-20
CN118207212A (zh) 2024-06-18
US20140343266A1 (en) 2014-11-20
AU2018229530A1 (en) 2018-10-04
WO2013100190A1 (ja) 2013-07-04

Similar Documents

Publication Publication Date Title
IN2014DN06220A (ja)
EP2828275A4 (en) SYNTHESIS OF 3-O-FUCOSYLLACTOSE TYPE TRISACCHARIDE AND ITS INTERMEDIATES
PH12016501761A1 (en) Antisense nucleic acids
LT3378862T (lt) Dihidropirimidinoizochinolinonai ir jų farmacinės kompozicijos, skirti išsėtinės sklerozės gydymui
IL225769A0 (en) Piperidine-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors
EP2544584A4 (en) ON THE BODY WORN LIFE SIGNAL MONITOR
IN2015DN02875A (ja)
EP2545161A4 (en) ENTEROBACTER SP. 638 AND METHOD FOR ITS USE
IL235349A0 (en) Therapeutic use of Chardonnay grape products
IT1401855B1 (it) Apparecchiatura per il trattamento di un prodotto.
ZA201307956B (en) Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor
IL225815A0 (en) Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors
EP2750715A4 (en) IDENTIFICATION OF SMALL MOLECULES THAT ENHANCE THE EXON THERAPEUTIC JUMP
IN2014CN00795A (ja)
IN2015DN01524A (ja)
HK1223294A1 (zh) 的治療應用
EP2971156A4 (en) Genes and gene signatures for diagnosis and treatment of melanoma
EP3052654A4 (en) Identification of structurally similar small molecules that enhance therapeutic exon skipping
ZA201408062B (en) Compositions and methods for the treatment of multiple sclerosis
MY165088A (en) Pharmaceutical compositions comprising alisporivir
ZA201306420B (en) Regulated gene expression systems and constructs thereof
HK1217689A1 (zh) 及其生物活性類似物的合成
ZA201408058B (en) Compositions and methods for the treatment of epilepsy
ZA201300083B (en) New drug combinations for the treatment of malaria
IT1406405B1 (it) Molecole peptidiche per il trattamento di patologie mitocondriali